Avid Bioservices (NASDAQ:CDMO) initiated with Overweight rating and $4 (72% upside) at First Analysis.
RadNet (NASDAQ:RDNT) initiated with Strong Buy rating and $15 (19% upside) price target at Raymond James.
Bluebird bio (NASDAQ:BLUE) initiated with Neutral rating at Janney.
Sabra Healthcare REIT (NASDAQ:SBRA) upgraded to Buy with a $24 (33% upside) price target at Mizuho Securities.
Quest Diagnostics (NYSE:DGX) upgraded to Equal Weight at Morgan Stanley.
Inovalon Holdings (NASDAQ:INOV) downgraded to Underweight with a $10 (16% downside risk) price target at Morgan Stanley.
Subscribe for full text news in your inbox